XHKG1477
Market cap419mUSD
Jan 07, Last price
4.05HKD
1D
-2.88%
1Q
-35.41%
IPO
-88.36%
Name
Ocumension Therapeutics
Chart & Performance
P/E
—
P/S
12.47
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.45%
Rev. gr., 5y
%
Revenues
246m
+54.99%
Net income
-380m
L-5.68%
CFO
-178m
L-11.33%
Earnings
Jun 20, 2025
Profile
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 246,367 54.99% | 158,957 183.11% | ||||
Cost of revenue | 504,775 | 614,137 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (258,408) | (455,180) | ||||
NOPBT Margin | ||||||
Operating Taxes | 307 | 414 | ||||
Tax Rate | ||||||
NOPAT | (258,715) | (455,594) | ||||
Net income | (379,787) -5.68% | (402,643) 198.74% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 4,133 | 1,718 | ||||
BB yield | ||||||
| Debt | ||||||
Debt current | 132,326 | 12,285 | ||||
Long-term debt | 23,640 | 46,869 | ||||
Deferred revenue | 30,090 | 30,090 | ||||
Other long-term liabilities | 30,090 | |||||
Net debt | (1,257,683) | (1,205,895) | ||||
| Cash flow | ||||||
Cash from operating activities | (177,927) | (200,657) | ||||
CAPEX | (80,911) | (310,003) | ||||
Cash from investing activities | (259,784) | 229,146 | ||||
Cash from financing activities | 108,660 | (9,222) | ||||
FCF | (278,297) | (537,801) | ||||
| Balance | ||||||
Cash | 1,049,501 | 1,288,447 | ||||
Long term investments | 364,148 | (23,398) | ||||
Excess cash | 1,401,331 | 1,257,101 | ||||
Stockholders' equity | (4,721,530) | (4,446,666) | ||||
Invested Capital | 7,809,571 | 7,283,516 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 649,185 | 632,532 | ||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (200,872) | (414,722) | ||||
EV/EBITDA | ||||||
Interest | 1,325 | 1,793 | ||||
Interest/NOPBT | ||||||